![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2004, p. 4907-4910, Vol. 48, No. 12
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.12.4907-4910.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Kuzell Institute, California Pacific Medical Center Research Institute, San Francisco, California,1 Department of Biomedical Sciences, College of Veterinary Medicine, and Department of Microbiology, College of Science, Oregon State University, Corvallis, Oregon2
Received 22 December 2003/ Returned for modification 8 February 2004/ Accepted 27 July 2004
 |
ABSTRACT |
|---|
 Top Abstract TextReferences |
|---|
|
TEXT |
|---|
|
TopAbstractTextReferences |
|---|
As an environmental bacterium, it has been shown to form biofilm in water collections and in urban pipes (8, 12). In addition, M. avium has been isolated from sauna walls in Finland (20).
The ability of mycobacteria to form biofilm has been recently linked to the production of glycopeptidolipid (18). A number of identified genes have been associated with the impaired ability of M. avium to form biofilm (L. Bermudez, M. Wu, Y. Yamazaki, Y. Li, and L. S. Young, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-1039, 2003).
In humans, M. avium can cause disseminated disease in individuals with AIDS, as well as localized infection, as observed in patients with chronic lung diseases, such as emphysema, and in patients undergoing peritoneal dialysis (1, 14, 23). More recently, M. avium lung infection in elderly women without any predisposing condition has been described, and these types of cases may be increasing (17).
The association of M. avium with chronic lung infection, a condition commonly resistant to treatment with antibiotics, has suggested the possibility that this bacterium could survive in the airways by assuming a phenotype associated with the formation of biofilm. Clinical experience shows that infection is frequently recurrent and that several cycles of antibiotic treatment are usually required to achieve cure. The protection from antibiotics of bacteria growing in biofilms has been previously described and probably depends on a combination of several factors (23). The most intuitive is that antibiotics fail to physically penetrate the biofilm.
Because of the potential clinical implications, we designed experiments in an attempt to obtain some information about the ability of clinically used anti-M. avium drugs to inhibit or prevent biofilm formation.
M. avium strains 101, 104, 109, and A5 were obtained from the blood of AIDS patients. The first three strains belong to serovars 1 (101 and 104) and 4 (109), while the serotype of A5 is unknown. Strain A5 was kindly provided by K. Eisenach (Little Rock, Ark.). Culture stocks were established following isolation, and bacteria used in the present study were obtained from the stock. Mycobacteria were grown in Middlebrook 7H10 aerobically at 37°C and an atmosphere of 5% CO2.
Testing for susceptibility to azithromycin, clarithromycin, and moxifloxacin was carried out by the BACTEC microdilution method as previously described (15). Bacteria were used at late log phase. Approximately 105 bacteria were added to the medium with different concentrations of antibiotics. The compounds were gifts from Pfizer (Groton, Conn.), Abbott (Abbott Park, Ill.), and Bayer (West Haven, Conn.), respectively. The antibiotics were prepared according to instructions from the manufacturers. They were further diluted in balanced Hanks' salt solution (HBSS; Difco), as previously reported, to the desired concentration (15). In addition, bacteria retrieved from biofilms were also examined for antibiotic sensitivity. Briefly, well-developed biofilm colonies were removed from the polyvinyl chloride (PVC) plates (Falcon 3911, Microtest III flexible assay plate; Becton Dickinson, San Diego, Calif.) and resuspended in 5 ml of HBSS. The suspension was agitated by vortex for 2 min. The bacterial suspension was then processed as described above (2, 3). To create a dispersed suspension, bacteria were passed through a 23-gauge needle 10 times and placed in a 15-ml polystyrene tube. After 5 min of rest at room temperature, the top half of the suspension was obtained and an aliquot was stained with acid-fast stain for observation under the microscope.
Biofilm was prepared as previously described (9). Briefly, 107 bacteria in 200 µl of HBSS were seeded in a PVC covered plastic 96-well microfilter plate. The biofilm was assayed by determining the ability of cells to adhere to wells, as reported previously (9). Following inoculation, plates were incubated at room temperature for up to 14 days. To measure biofilm formation, supernatant was removed from the well and 25 µl of a 1% crystal violet solution (Sigma Co., St. Louis, Mo.) was added to each well (the dye stains bacterial cells but not the PVC material). The plates were incubated at room temperature for 15 min, rinsed vigorously four times with water, and blotted on paper. The crystal violet was dissolved in 95% ethanol, and the presence of dissolved biofilm was scored by measuring A570 with a spectophotometer, as previously described (9). Biofilm of M. avium 101 was also prepared for scanning electron microscopy as previously described (4).
To determine if azithromycin, clarithromycin, and moxifloxacin had any effect on M. avium biofilm, bacterial suspensions of 107 bacteria were seeded in the PVC plates and exposed to the antibiotics at a 50% subinhibitory concentration from day 0. Antibiotics were maintained in the wells for the duration of the experiments. Biofilm formation was scored at day 14. In some experiments, antibiotics were added at days 0, 2, 4, and 7 after seeding bacteria in order to determine if suppressive activity could be observed in the course of biofilm formation. Biofilms were then monitored for 14 days after the addition of antibiotics and then scored. Assays in which clarithromycin was added to established M. avium biofilms were also carried out. Briefly, established M. avium biofilms (14 days) were treated with clarithromycin at 50% of the MIC (1 µg/ml) or at the MIC (2 µg/ml) for an additional 14 days. Thereafter, the amount of biofilm on the PVC plate was determined and compared with biofilm not treated with clarithromycin.
Each experiment was repeated at least four times, and the results are expressed as the means ± standard deviations. The experimental results were compared with the controls and analyzed by the nonparametric Mann-Whitney test. A P value of <0.05 was considered significant.
Figure 1 shows the biofilm formed by strain 101. The concentrations of azithromycin, clarithromycin, and moxifloxacin that were inhibitory to M. avium strains 101, 109, 104, and A5 were 16, 2, and 2 µg/ml, respectively. Because biofilm can select for antibiotic-resistant strains, established M. avium biofilms were dispersed and the strains were tested for susceptibility to antibiotics. The MICs for the biofilm bacteria were the same as those for the planktonic bacteria, demonstrating that bacteria obtained from biofilm maintain the same antibiotic susceptibility observed in planktonic bacteria.
|
|
|
In this work we showed that clarithromycin and, less efficiently, azithromycin but not moxifloxacin, three compounds with potent anti-M. avium activity, were able to inhibit the formation of M. avium biofilm on PVC. The effect of clarithromycin was observed at a subinhibitory concentration at which the bacterial growth is not inhibited. In addition, clarithromycin, added up to 4 days after M. avium seeding on PVC plates, was still able to significantly inhibit the formation of biofilm. In contrast, the antibiotic had no effect on established biofilm. One should consider, however, that at other concentrations azithromycin might be active.
One of the major problems for physicians dealing with patients with M. avium infection of the lung is the recurrence of the disease, even following therapy with an active antibiotic (21). The reason for therapy failure in this population is unknown but could be related to biofilm formation in the airways. M. avium has the ability to form biofilm in urban pipes and several surfaces (13). A number of studies have demonstrated that, in patients with bronchiectasis and in those with cystic fibrosis, the inefficiency of antibiotics used to treat the superimposed infection is related to the ability of the microorganisms to form biofilm (10, 19). In our study, bacteria recovered from established biofilm were still susceptible to azithromycin, clarithromycin, and moxifloxacin, despite the resistance of the biofilm to the action of the antibiotics.
Two explanations have long dominated the debate for the reduced antibiotic susceptibility that is observed in biofilms. The first and most intuitive is that the antibiotic fails to physically penetrate the biofilm. The second explanation is that nutrient limitation leads to slow growth or stationary-phase existence for many of the cells in a biofilm, reducing their antibiotic susceptibility (7). More recently, it has been shown that a third possibility exists. Pseudomonas aeruginosa biofilms bind to antibiotics, inactivating them (16). Whether any component of the M. avium biofilm is associated with similar mechanisms is currently unknown. M. avium biofilm was resistant to the action of antibiotics once established, but the mechanisms of resistance are unknown. The third possibility is less likely than the other two to be the explanation, based on past observation that quinolones, but not macrolides, are able to kill nonreplicating M. avium (6). A recent study has suggested that oxygen limitation and low metabolic activity are responsible for the tolerance of Pseudomonas aeruginosa biofilm to ciprofloxacin and tobramycin (22).
The observation that macrolides are more efficient that quinolones in preventing M. avium biofilm is interesting. Additionally, our finding that clarithromycin was more effective than azithromycin in suppressing biofilm formation is quite intriguing. Clarithromycin has been shown to be more active than azithromycin against M. avium in mice on a weight basis and in short-term treatment, while azithromycin is superior in deep tissues, which could explain the superior activity of clarithromycin in biofilms (5). Alternately, clarithromycin could have more activity against stationary-phase organisms than azithromycin. However, there is no evidence that macrolides have activity against nonreplicating M. avium. Although the difference in susceptibility could be explained by the ability to penetrate biofilm, there is no current evidence to indicate that clarithromycin would penetrate M. avium biofilm with more efficiency than azithromycin.
Recently, we and others have identified mycobacterial genes associated with biofilm formation (18; L Bermudez et al., 43rd ICAAC). The selection of antibiotics that target those genes in M. avium, even at subinhibitory concentrations, may have clinical applications. Our results demonstrated that clarithromycin, if employed early, has the potential to have a significant impact on biofilm formation, which would potentially prevent the extension of the disease in the lung. Future work will attempt to confirm these findings in an animal model.
|
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant from Abbott Laboratories, and by grant AI-25140 from the National Institute of Allergy and Infectious Diseases.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractTextReferences |
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |
